Single Autologous Transplant Followed by Consolidation and Maintenance for Participants ≥ 65 Years of Age Diagnosed With Multiple Myeloma or a Related Plasma Cell Malignancy
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Autologous stem cell therapy; Bortezomib; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Lenalidomide; Melphalan; Pegfilgrastim; Thalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 24 Dec 2020 Biomarkers information updated
- 20 May 2013 New trial record